GlaxoSmithKline PLC (GSK.LN) Wednesday announced a regulatory submission for mepolizumab, used to treat the rare disease Eosinophilic Granulomatosis with Polyangiitis, to be made available in the U.S.
Shares at 1516GMT, down 34 pence, or 2%, at 1,664 pence valuing the company at GBP81.86 billion.
Continue Reading Below
-Write to Rory Gallivan at email@example.com; Twitter: @RoryGallivan
(END) Dow Jones Newswires
June 28, 2017 11:32 ET (15:32 GMT)